Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof

A pharmaceutical composition comprising (i) a compound of formula (I-A):

• or a pharmaceutically acceptable salt of any of the foregoing, wherein:
• Y1 is CH or N;
• Rx and Rz are independently H, halo, C1-6alkyl, or —NH2, wherein, when Y1 is CH, the C1-6alkyl of Rx or Rz may be optionally substituted with one or more halo;
• Ry is (i) C1-6alkyl, or (ii) C3-10cycloalkyl, wherein the C3-10cycloalkyl is optionally substituted with one or more halo or C1-6alkyl;
• Rk is H, halo, —OH, —NH2, or —NH—C(O)C1-6alkyl;
• R2 is C1-6alkyl, wherein the C1-6alkyl of R2 is substituted with one or more Ra, wherein Ra is —OH or 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of Ra is optionally substituted with one or more Rb;
• and
• Rb is halo, C1-6alkyl, C1-6alkoxy, —NH2, —NH(C1-6alkyl), —N(C1-6alkyl)2, C3-10cycloalkyl, 3-15 membered heterocyclyl, or —C(O)—C1-6alkoxy, wherein the C1-6alkyl of Rb is optionally substituted with one or more halo, —NH2, —NH(C1-6alkyl), —N(C1-6alkyl)2, —NH—C(O)C1-6alkyl, or —NH—C(O)—C1-6alkoxy, and the 3-15-membered heterocyclyl of Rb is optionally substituted with one or more halo or —C(O)—C1-6alkoxy,
• wherein the moiety represented by
• has a stereochemical configuration of the formula:
• and (ii) one or more pharmaceutically acceptable excipients.